Search
Levobupivacaine
go.drugbank.com/drugs/DB01002ApprovedInvestigationalWithdrawnto an anesthetic. … Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine.
Piracetam
go.drugbank.com/drugs/DB09210ApprovedWithdrawnPiracetam has effects on the vascular system by reducing erythrocyte adhesion to the vascular endothelium, hindering vasospasms and facilitating microcirculation [A31532]. … It shares the same 2-oxo-pyrrolidone base structure with pyroglutamic acid and is a cyclic derivative of the neurotransmitter γ-aminobutyric acid (GABA).
Ulobetasol
go.drugbank.com/drugs/DB00596Approved[A215597] It is structurally related to [clobetasol].[A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.
Grazoprevir
go.drugbank.com/drugs/DB11575ApprovedThe substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. … Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without [DB00811] depending on the the presence of resistance associated amino acid substitutions
Revakinagene taroretcel
go.drugbank.com/drugs/DB05344ApprovedInvestigational[L52270] Revakinagene taroretcel delivers CNTF to the retina to lower the extent of neuroregeneration. … [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2.
Tenecteplase
go.drugbank.com/drugs/DB00031ApprovedInvestigational296-299 in the protease domain. … It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids
Almitrine
go.drugbank.com/drugs/DB01430ApprovedIt is also reported to have a potentially beneficial effect in treating the noctural oxygen desaturation without impairing the quality of sleep. … It is used in the treatment of chronic obstructive pulmonary disease.
Moxidectin
go.drugbank.com/drugs/DB11431ApprovedInvestigationalVet approvedDue to these modifications, moxidectin is classified as a second generation macrocyclic lactone. … It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of the milbemycin class.
Tislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigationalIt was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis. … [L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349]
Micafungin
go.drugbank.com/drugs/DB01141ApprovedInvestigationalIt belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.